|
Sosei gains 25.6-percent stake in MiNA Therapeutics
June 2017
SHARING OPTIONS:
TOKYO & LONDON—Under a recent definitive agreement, Sosei Group Corp. will make an investment in and gain an exclusive option to potentially acquire
biopharmaceutical company MiNA Therapeutics. Sosei will invest £35 million into MiNA Therapeutics
in return for a 25.6-percent equity share and an exclusive option to acquire further stakes and possibly the company for an additional £140 million.
Should Sosei fully exercise its option, MiNA's shareholders could receive up to £240 million based on the achievement of development and regulatory
milestones and royalties.
Sosei CEO Peter Bains commented, “We are very pleased to enter into this agreement with
MiNA, which strongly supports Sosei’s vision to become a global biotechnology company and is consistent with our inorganic strategy to both accelerate
Sosei’s pipeline development and to identify complementary technologies to our world-leading Heptares GPCR platform.”
Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|